Clinical TrialMay 6, 2026, 07:34 AM
Medicus Pharma's D-MNA Phase 2 Shows Positive Dose Response for BCC
AI Summary
Medicus Pharma Ltd. announced positive dose response results from an expanded dataset analysis of its Phase 2 SKNJCT-003 study for Doxorubicin Microneedle Array (D-MNA) in treating nodular basal cell carcinoma (BCC). The study demonstrated progressive and dose-dependent improvement, with the 200µg D-MNA cohort showing 64% clinical clearance and 55% histological clearance at Day 57, significantly outperforming the device-only control. The D-MNA also exhibited a favorable safety and tolerability profile, reinforcing its therapeutic potential and supporting future registrational discussions with the FDA.
Key Highlights
- Medicus Pharma's D-MNA Phase 2 SKNJCT-003 study showed positive dose response for nodular basal cell carcinoma (BCC).
- At Day 57, the 200µg D-MNA cohort achieved 64% clinical clearance and 55% histological clearance.
- The device-only control group showed 29% clinical and histological clearance at Day 57.
- D-MNA demonstrated a favorable safety profile with no drug-related serious adverse events.
- Findings strengthen the therapeutic profile and support future FDA registrational discussions.
- SkinJect™ addresses a ~$2 billion market opportunity for non-melanoma skin diseases.
Price Impact
More from MDCX